Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

PHASE4RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

July 12, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

July 30, 2026

Conditions
HIV Infections
Interventions
DRUG

Standard Medical Therapy

Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet.

DRUG

dual therapy

Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs

Trial Locations (1)

02990

RECRUITING

Hospital de Infectología, Centro Médico Nacional La Raza, Mexico City

All Listed Sponsors
lead

José Antonio Mata Marín

OTHER_GOV